ODN-based drugs for targeting of extracellular proteins.
In this work a novel approach to identify new therapeutic targets consisting of serum proteins which contain an oligonucleotide binding domain is presented.
Bionucleon Srl, Colleretto Giacosa (TO), Italy. bucci@bioindustrypark.it
E M
EM
Bucci
M
M
Valente
D
D
Musumeci
R
R
Sapio
V
V
Anrò
Giovanni N
GN
Roviello
M
M
Moccia
D001665:Binding Sites; D001798:Blood Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics*; D015195:Drug Design; D018390:Gene Targeting; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics; D006801:Humans; D046911:Macromolecular Substances; D008958:Models, Molecular; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000235:genetics* / Q000494:pharmacology*
D001798:Blood Proteins; D024243:HMGB1 Protein; D046911:Macromolecular Substances; D009838:Oligodeoxyribonucleotides